Deutivacaftor

Major

Deutivacaftor Relugolix Orgovyx Explained Increased relugolix exposure Details Deutivacaftor Colchicine Colcrys Explained Increased exposure to P-gp substrates and increased risk of P-gp substrates-related adverse effects Details Deutivacaftor Abrocitinib Cibinqo Explained Increased CYP2C9 substrate exposure Details Deutivacaftor Avatrombopag Doptelet Increased CYP2C9 substrate exposure Details Deutivacaftor Cyclosporine Injection Atopica Increased exposure to P-gp substrates and increased risk of P-gp substrates-related adverse effects Details Deutivacaftor Cyclosporine Ophthalmic Cequa Increased exposure to P-gp substrates and increased risk of P-gp substrates-related adverse effects Details Deutivacaftor Deuruxolitinib Increased CYP2C9 substrate exposure Details Deutivacaftor Diclofenac Ophthalmic Voltaren® Eye Drops Increased CYP2C9 substrate exposure Details Deutivacaftor Diclofenac Topical (Actinic Keratosis) Pennsaid Increased CYP2C9 substrate exposure Details Deutivacaftor Diclofenac Topical (Arthritis Pain) Pennsaid® Increased CYP2C9 substrate exposure Details Deutivacaftor Diclofenac Transdermal Patch Flector Increased CYP2C9 substrate exposure Details Deutivacaftor Digoxin Cardoxin® Increased exposure to P-gp substrates and increased risk of P-gp substrates-related adverse effects Details Deutivacaftor Dronabinol Marinol Increased CYP2C9 substrate exposure Details Deutivacaftor Erdafitinib Balversa Increased CYP2C9 substrate exposure Details Deutivacaftor Everolimus Afinitor Increased exposure to P-gp substrates and increased risk of P-gp substrates-related adverse effects Details Deutivacaftor Flurbiprofen Ansaid Increased CYP2C9 substrate exposure Details Deutivacaftor Flurbiprofen Ophthalmic Ocufen Increased CYP2C9 substrate exposure Details Deutivacaftor Fluvastatin Lescol Increased CYP2C9 substrate exposure Details Deutivacaftor Glimepiride Amaryl Increased CYP2C9 substrate exposure Details Deutivacaftor Glipizide Glucotrol Increased CYP2C9 substrate exposure Details Deutivacaftor Ibuprofen Addaprin Increased CYP2C9 substrate exposure Details Deutivacaftor Irbesartan Avapro Increased CYP2C9 substrate exposure Details Deutivacaftor Ketoconazole Topical Extina® Foam Increased deutivacaftor exposure and an increased risk of deutivacaftor-related adverse reactions Details Deutivacaftor Lefamulin Xenleta Increased deutivacaftor exposure and an increased risk of deutivacaftor-related adverse reactions Details Deutivacaftor Lenacapavir Injection Sunlenca Increased deutivacaftor exposure and an increased risk of deutivacaftor-related adverse reactions Details Deutivacaftor Lenacapavir Oral Sunlenca Increased deutivacaftor exposure and an increased risk of deutivacaftor-related adverse reactions Details Deutivacaftor Letermovir Injection Prevymis Increased deutivacaftor exposure and an increased risk of deutivacaftor-related adverse reactions Details Deutivacaftor Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Deutivacaftor Losartan Arbli Increased CYP2C9 substrate exposure Details Deutivacaftor Macitentan Opsumit Increased CYP2C9 substrate exposure Details Deutivacaftor Meloxicam Alloxate Increased CYP2C9 substrate exposure Details Deutivacaftor Meloxicam Injection Alloxate Increased CYP2C9 substrate exposure Details Deutivacaftor Mitapivat Aqvesme Reduced deutivacaftor exposure and reduced efficacy of deutivacaftor Details Deutivacaftor Nafcillin Injection Unipen® Injection Reduced deutivacaftor exposure and reduced efficacy of deutivacaftor Details Deutivacaftor Nateglinide Starlix® Increased CYP2C9 substrate exposure Details